• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Herpes infection of the cornea
The clear tissue at the front of the eye is known as the cornea, and it must remain crystal clear in order for an individual to see clearly. The herpes viruses can infect the cornea, causing damage to tissue and possibly causing lasting visual impairment if not quickly identified and treated. Herpes simplex: the cold sore virus One of the most common infections of the cornea is caused by the herpes simplex virus (HSV type I and HSV type II), or the cold sore virus. The most common question from patients with HSV infection of the cornea is “How did I get this?” The answer is fairly simple. The virus is everywhere, and e...
Source: Harvard Health Blog - May 20, 2019 Category: Consumer Health News Authors: Emma Davies, MD Tags: Eye Health Infectious diseases Source Type: blogs

Herpes Zoster.
This article summarizes the background, evidence, and guidelines for the diagnosis, complications, treatment, and prevention of herpes zoster. Diagnosis of challenging cases relies on polymerase chain reaction as the preferred test. Treatment focuses on optimal use of antiviral therapy and analgesics. Prevention emphasizes utilization of a new recombinant zoster vaccine, which reduces the incidence of herpes zoster by more than 90% and is preferred to the live attenuated herpes zoster vaccine. PMID: 30083718 [PubMed - in process]
Source: Annals of Internal Medicine - August 7, 2018 Category: Internal Medicine Authors: Schmader K Tags: Ann Intern Med Source Type: research

How Long Does Shingles Last In The Elderly?
View Original Article Here: How Long Does Shingles Last In The Elderly? Shingles is a viral infection that follows a varicella-zoster infection, although it can take decades for symptoms of the secondary disease to emerge. The condition presents as a painful and blistering rash, but it is not life-threatening. According to the Center for Disease Control, there are nearly one million cases in the United States each year, and almost half of those cases are in older adults over age 60. Some people only see one instance of the illness, while others have recurring symptoms, but 30 percent of Americans will develop shingles at s...
Source: Shield My Senior - December 8, 2017 Category: Geriatrics Authors: Vin Tags: Senior Safety Source Type: blogs

An Infection that Vaccine Doesn't Prevent over Time
​BY NATALIE CAZEAU, ​MSC; ERICA ROMAN HERNANDEZ; KINZA IJAZ; AMY SCHEUERMANN; AHMED RAZIUDDIN, MDA 43-year-old man presented to the ED with a rash in a C7 dermatomal pattern that was burning and painful. The patient said the rash began three weeks before the ED visit as a group of little blisters on his right upper back and extending down his right arm. The patient was worried and in mild distress as the rash continued to burn, and he reported numbness to the area. He mentioned he had received the shingles vaccine in the past.​The patient's rash was yellow, crusty, and tender upon palpation. The area was hyperke...
Source: The Case Files - October 25, 2017 Category: Emergency Medicine Tags: Blog Posts Source Type: research

Fight Aging! Newsletter, May 16th 2016
In this study the authors demonstrate that, as in many other cases, the methodology of delivery matters just as much as the details of the cells used: Retinal and macular degenerative diseases affect millions of people worldwide. Similar to other neurodegenerative diseases, there are no effective treatments that can stop retinal degeneration or restore degenerative retina. Recent advances in stem cell technology led to development of novel cell-based therapies, some are already in phase I/II clinical trials. Studies from our group and others suggest that human bone marrow-derived mesenchymal stem cells (hBM-MSC) m...
Source: Fight Aging! - May 15, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs